Table 1.
The clinical and transcriptomic characteristics in two cohorts.
| Characteristics | The discovery cohort (n = 174) | The validation cohort (n = 72) | p-Value |
|---|---|---|---|
| Age | ≤50 years: 95 (54.6)/>50 years: 79 (45.4) | ≤50 years: 30 (41.7)/>50 years: 42 (58.3) | 0.088 a |
| IHC ER status PR status HER2 status Ki67 status |
P: 127 (73.0)/N: 47 (27.0) P: 111 (63.8)/N: 63 (36.2) P: 36 (20.7)/N: 138 (79.3) High: 136 (78.2)/low: 38 (21.8) |
P: 61 (84.7)/N: 11 (15.3) P: 55 (76.4)/N: 17 (23.6) P: 14 (19.4)/N: 37 (51.4)/NA: 21 (29.2) NA |
0.071 a 0.077 a 0.407 a NA |
| IHC-based subtypes Luminal-A Luminal-B HER2-positive Triple-negative |
28 (16.1) 101 (58.1) 15 (8.6) 30 (17.2) |
NA NA NA NA |
NA NA NA NA |
| PAM50 intrinsic subtypes Luminal-A Luminal-B HER2-enriched Basal-like Normal-like |
49 (28.1) 43 (24.7) 29 (16.7) 43 (24.7) 10 (5.8) |
44 (61.1) 9 (12.5) 5 (6.9) 10 (13.9) 4 (5.6) |
<0.001 b |
| Prognostic risk MammaPrint Oncotype DX |
High: 131 (75.3)/low: 43 (24.7) High: 168 (96.6)/intermediate or low: 6 (3.4) |
High: 55 (76.4)/low: 17 (23.6) High: 67 (93.1)/intermediate or low: 5 (6.9) |
0.984 a 0.385 a |
| Pathological stage I stage II stage III stage |
55 (31.6) 94 (54.0) 25 (14.4) |
17 (23.6) 47 (65.3) 8 (11.1) |
0.267 a |
Clinical, MRI, and molecular data for both cohorts were available. The patient distribution of the two cohorts was not different except for the PAM50 molecular subtypes. Unless otherwise indicated, data are number of samples or the p-value of statistical test, and the data in parentheses are percentages.
P, receptor status; N, negative; NA, not available; IHC, immunohistochemistry; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
a
p-Value for the two-sided Pearson’s chi-squared test.
b
p-Value for the two-sided Fisher’s exact test.